Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts
Xiaohua Ni, … , Theodore L. DeWeese, Shawn E. Lupold
Xiaohua Ni, … , Theodore L. DeWeese, Shawn E. Lupold
Published May 9, 2011
Citation Information: J Clin Invest. 2011;121(6):2383-2390. https://doi.org/10.1172/JCI45109.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 10

Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts

  • Text
  • PDF
Abstract

Dose-escalated radiation therapy for localized prostate cancer (PCa) has a clear therapeutic benefit; however, escalated doses may also increase injury to noncancerous tissues. Radiosensitizing agents can improve ionizing radiation (IR) potency, but without targeted delivery, these agents will also sensitize surrounding normal tissues. Here we describe the development of prostate-targeted RNAi agents that selectively sensitized prostate-specific membrane antigen–positive (PSMA-positive) cells to IR. siRNA library screens identified DNA-activated protein kinase, catalytic polypeptide (DNAPK) as an ideal radiosensitization target. DNAPK shRNAs, delivered by PSMA-targeting RNA aptamers, selectively reduced DNAPK in PCa cells, xenografts, and human prostate tissues. Aptamer-targeted DNAPK shRNAs, combined with IR, dramatically and specifically enhanced PSMA-positive tumor response to IR. These findings support aptamer-shRNA chimeras as selective sensitizing agents for the improved treatment of high-risk localized PCa.

Authors

Xiaohua Ni, Yonggang Zhang, Judit Ribas, Wasim H. Chowdhury, Mark Castanares, Zhewei Zhang, Marikki Laiho, Theodore L. DeWeese, Shawn E. Lupold

×

Total citations by year

Year: 2025 2024 2023 2022 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Total
Citations: 3 2 1 1 3 2 5 2 5 13 13 11 10 5 1 77
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2013 (11)

Title and authors Publication Year
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Alexey Berezhnoy, Iris Castro, Agata Levay, Thomas R. Malek, Eli Gilboa
Journal of Clinical Investigation 2013
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
LI Hernandez, KS Flenker, FJ Hernandez, AJ Klingelhutz, JO 2nd, PH Giangrande
Pharmaceuticals (Basel, Switzerland) 2013
Recombinant AAV as a Platform for Translating the Therapeutic Potential of RNA Interference
F Borel, MA Kay, C Mueller
Molecular Therapy 2013
Ex vivo culture of human prostate tissue and drug development
MM Centenera, GV Raj, KE Knudsen, WD Tilley, LM Butler
Nature Reviews Urology 2013
Current progress on aptamer-targeted oligonucleotide therapeutics
JP Dassie, PH Giangrande
Therapeutic Delivery 2013
Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate
SL Maund, R Nolley, DM Peehl
Laboratory Investigation 2013
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer
S Alcorn, AJ Walker, N Gandhi, A Narang, AT Wild, RK Hales, JM Herman, DY Song, TL Deweese, ES Antonarakis, PT Tran
International journal of molecular sciences 2013
Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages
O Boyacioglu, CH Stuart, G Kulik, WH Gmeiner
Molecular Therapy — Nucleic Acids 2013
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer
ZH Peng, M Sima, ME Salama, P Kopečková, J Kopeček
Journal of Drug Targeting 2013
Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay
E Gilboa
Immunologic Research 2013
PET imaging in prostate cancer: focus on prostate-specific membrane antigen.
Mease RC, Foss CA, Pomper MG
Current topics in medicinal chemistry 2013

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
Referenced in 6 patents
Referenced in 1 Wikipedia pages
94 readers on Mendeley
1 readers on CiteULike
See more details